Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Fort Washington, PA 19034

DIA 2020 Global Annual Meeting

Patient-Centricity: How do We Measure Progress in Involving Patients in Drug Development and Drug Safety?

Session Chair(s)

Mariette  Boerstoel-Streefland, MD, MBA, MS

Mariette Boerstoel-Streefland, MD, MBA, MS

Senior Vice President, Worldwide Safety Officer

Bristol-Myers Squibb Company, United States

This session will highlight progress to date in identifying metrics to assess patient involvement in drug development and drug safety, and the current challenges to, and benefits of, achieving a more patient-centric culture within the pharmaceutical industry. Perspectives on this topic will be provided by representatives from IMI-PARADIGM, industry, the patient advocacy sector, and the US FDA. Join the DIA Patient Engagement Community for a follow up round table discussion (session #216 L-RT) on Tuesday, June 16, 10:45AM - 11:30AM.

Learning Objective : Discuss how to use a framework to guide selection of appropriate patient-centricity metrics for use within a pharmaceutical company; Describe the types of metrics that have been developed to date to measure patient involvement in drug development, including drug safety; Identify key challenges to implementing patient-centricity metrics within a pharmaceutical company and identify specific strategies to overcome those barriers.

Speaker(s)

Robyn  Bent, BSN, MS, RN

FDA Update

Robyn Bent, BSN, MS, RN

FDA, United States

Director, Patient Focused Drug Development, OCD, CDER

Katherine  Capperella

Measuring Patient Engagement Progress: Part of a Comprehensive Change Leadership Plan

Katherine Capperella

Johnson & Johnson, United States

VP, Global Patient Engagement Leader

Elisabeth  Oehrlein, PhD, MS

Patient-Centricity: How do We Measure Progress in Involving Patients in Drug Development and Drug Safety? - Policy Update

Elisabeth Oehrlein, PhD, MS

National Health Council (NHC), United States

Senior Director, Research and Programs

Tjerk Jan  Schuitmaker, PhD, MSc

What Frameworks and Metrics Exist for Measuring Patient-Centricity in Drug Development and Drug Safety

Tjerk Jan Schuitmaker, PhD, MSc

Athena Institute of the Vrije University of Amsterdam , Netherlands

IMI-PARADIGM; Assistant Professor

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.